1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Morphine Sulfate Extended-Release with Sequestered Naltrexone Hydrochloride Capsules

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>EMBEDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Not determined</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as opioid analgesic</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: Yellow, blue blue/violet, pink, light peach, green hard gelatin capsules

Signal Word: DANGER

Statement of Hazard:
- May cause harm to the unborn child.
- May cause harm to breastfed babies.
- Suspected of causing genetic defects

Additional Hazard Information:
- Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.

Known Clinical Effects:
Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, blurred vision and dilated pupils. Cases of overdosage may also lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia. Additionally symptoms of dependence/withdrawal may occur. Secreted in human breast milk. May cause harm to breastfed babies.

EU Indication of danger: Toxic to reproduction, Category 2
Mutagenic: Category 3

EU Hazard Symbols: T

EU Risk Phrases:
2. HAZARDS IDENTIFICATION

R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.
R68 - Possible risk of irreversible effects.

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine Sulfate</td>
<td>64-31-3</td>
<td>200-582-8</td>
<td>Xn;R22 Muta.Cat.3;R68 Repr.Cat.2;R61 R64</td>
<td>18</td>
</tr>
<tr>
<td>Naltrexone hydrochloride</td>
<td>16676-29-2</td>
<td>240-723-0</td>
<td>Xn;R22 Repr.Cat.2;R61 R64</td>
<td>0.75</td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sugar</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ammonio methacrylate coploymer</td>
<td>33434-24-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Ascorbic acid (Vitamin C)</td>
<td>50-81-7</td>
<td>200-066-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Dibutyl sebacate</td>
<td>109-43-3</td>
<td>203-672-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Ethylcellulose</td>
<td>9004-57-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>9004-64-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Methacrylic Acid Copolymer, Type C</td>
<td>Not Assigned</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Dibutyl sebacate
Latvia OEL - TWA 10 mg/m³
Lithuania OEL - TWA 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA) 2 mg/m³
Australia TWA 2.5 mg/m³
Austria OEL - MAKs 2 mg/m³
Belgium OEL - TWA 2 mg/m³
Bulgaria OEL - TWA 1.0 fiber/cm³
6.0 mg/m³
3.0 mg/m³

Czech Republic OEL - TWA 2.0 mg/m³
10 mg/m³

Denmark OEL - TWA 0.3 fiber/cm³

Finland OEL - TWA 0.5 fiber/cm³
5 mg/m³

Greece OEL - TWA 10 mg/m³
2 mg/m³

Hungary OEL - TWA 2 mg/m³

Ireland OEL - TWAs 10 mg/m³
0.8 mg/m³

Lithuania OEL - TWA 2 mg/m³
1 mg/m³

Netherlands OEL - TWA 0.25 mg/m³

OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf

Poland OEL - TWA 4.0 mg/m³
1.0 mg/m³

Portugal OEL - TWA 2 mg/m³

Slovakia OEL - TWA 2 mg/m³
10 mg/m³

Slovenia OEL - TWA 2 mg/m³

Spain OEL - TWA 2 mg/m³

Sweden OEL - TWAs 2 mg/m³
1 mg/m³

Sodium chloride

Latvia OEL - TWA 5 mg/m³

Lithuania OEL - TWA 5 mg/m³

Sugar

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³
Estonia OEL - TWA 10 mg/m³
France OEL - TWA 10 mg/m³
Ireland OEL - TWAs 10 mg/m³
Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 10 mg/m³
OSHA - Final PELs - TWAs: 15 mg/m³
Portugal OEL - TWA 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:
Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Wear safety glasses or goggles if eye contact is possible.
- Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Physical State: Hard-gelatin Capsule
- Color: Blue, blue violet yellow, pink, Light peach, green
- Molecular Formula: Mixture
- Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

- Chemical Stability: Stable under normal conditions of use.
- Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
- Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Ascorbic acid (Vitamin C)
- Rat Oral LD50 11.9 g/kg

Naltrexone hydrochloride
- Rat Oral LD50 1450 mg/kg

Morphine Sulfate
- Rat Oral LD50 461 mg/kg
- Rat Para-periosteal LD50 70 mg/kg
- Rat Intraperitoneal LD50 235 mg/kg
- Mouse Oral LD50 600 mg/kg
- Mouse Intravenous LD50 156 mg/kg

Sodium lauryl sulfate
- Rat Oral LD50 1288 mg/kg

Talc (non-asbestiform)
- Rat Oral LD50 > 1600 mg/kg

Magnesium stearate
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

Sodium chloride
- Rat Oral LD50 3000 mg/kg
- Mouse Oral LD50 4000 mg/kg

Sugar
- Rat Oral LD50 29700 mg/kg
- Mouse Oral LD50 14000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium lauryl sulfate
- Eye Irritation Rabbit Moderate
- Skin Irritation Rabbit Mild Moderate
- Skin Sensitization - GPMT Guinea Pig Negative
- Skin Sensitization - LLNA Mouse Negative

Sodium chloride
- Eye Irritation Rabbit Moderate
- Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Morphine Sulfate
18 Week(s) Rat Oral 60 g/kg LOAEL Lungs
15 Day(s) Rat Subcutaneous 3144 mg/kg LOAEL Kidney, Ureter, Bladder
9 Week(s) Rat Subcutaneous 3150 mg/kg LOAEL

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Naltrexone hydrochloride
Fertility and Embryonic Development Rat Oral 30 mg/kg/day LOAEL Embryotoxicity
Fertility and Embryonic Development Rabbit Oral 60 mg/kg/day LOAEL Embryotoxicity
Embryo / Fetal Development Rat Oral 200 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rabbit Oral 200 mg/kg/day NOAEL Not Teratogenic

Morphine Sulfate
Embryo / Fetal Development Mouse Subcutaneous 0.15 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Hamster Subcutaneous 35 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Mouse Oral 200 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Rat Subcutaneous 35 mg/kg LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Naltrexone hydrochloride
In Vitro Unscheduled DNA Synthesis Human Positive
Mitotic Gene Conversion Bacteria Negative
Bacterial Mutagenicity (Ames) Salmonella Equivocal
In Vivo Chromosome Aberration Mouse Negative

Morphine Sulfate
In Vivo Micronucleus Mouse Positive
In Vivo Chromosome Aberration Mouse Lymphocytes Positive
In Vitro Direct DNA Damage Human Lymphocytes Positive
In Vitro Chromosome Aberration Mouse Negative
Dominant Lethal Assay Drosophila Negative

Sodium lauryl sulfate
Bacterial Mutagenicity (Ames) Salmonella Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Naltrexone hydrochloride
2 Year(s) Mouse Oral NOAEL Not carcinogenic
2 Year(s) Rat Oral 100 mg/kg/day LOAEL Tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Talc (non-asbestiform)
IARC: Group 3 (Not Classifiable)
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties of the formulation have not been thoroughly investigated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)
Sodium lauryl sulfate
*Oncorhynchus mykiss* (Rainbow Trout)  LC50  96 Hours  3.6 mg/L

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn

EU Indication of danger: Toxic to reproduction, Category 2
Mutagenic: Category 3

EU Risk Phrases:
- R61 - May cause harm to the unborn child.
- R64 - May cause harm to breastfed babies.
- R68 - Possible risk of irreversible effects.

EU Safety Phrases:
- S22 - Do not breathe dust.
- S36/37 - Wear suitable protective clothing and gloves.
- S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
DANGER
May cause harm to the unborn child.
May cause harm to breastfed babies.
Suspected of causing genetic defects
15. REGULATORY INFORMATION

Canada - WHMIS: Classifications

WHMIS hazard class:
D1b  toxic materials
D2a  very toxic materials

Ammonio methacrylate coploymer
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present

Ascorbic acid (Vitamin C)
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present
  REACH - Annex IV - Exemptions from the obligations of Register:
  EU EINECS/ELINCS List  200-066-2

Dibutyl sebacate
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present
  EU EINECS/ELINCS List  203-672-5

Ethycellulose
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present

Hydroxypropyl cellulose
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present

Morphine Sulfate
  U.S. Drug Enforcement Administration:  Schedule II
  Australia (AICS):  Present
  EU EINECS/ELINCS List  200-582-8

Naltrexone hydrochloride
  EU EINECS/ELINCS List  240-723-0

Sodium lauryl sulfate
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present
  Standard for the Uniform Scheduling for Drugs and Poisons:
  EU EINECS/ELINCS List  205-788-1

Talc (non-asbestiform)
  Inventory - United States TSCA - Sect. 8(b)  Present
  Australia (AICS):  Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>238-877-9</td>
</tr>
<tr>
<td>Sugar</td>
<td></td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>200-334-9</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td></td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the obligations of Register:</td>
<td>209-150-3</td>
</tr>
</tbody>
</table>

Additional Information: U.S. Drug Enforcement Agency Controlled Drug Substance, Schedule II

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.
R68 - Possible risks of irreversible effects.

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information. Pfizer proprietary drug development information.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet